Compare Stocks: ETHZ, CGC, LRMR, and EPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$0.93 -2.8%	$0.97	$0.84 ▼ $2.38	$429.45M	0.81	2.19 million shs	2.08 million shs
EPRX Eupraxia Pharmaceuticals	$6.52 +0.2%	$6.44	$5.04 ▼ $9.32	$423.27M	1.08	360,517 shs	258,770 shs
ETHZ Flag Ship Acquisition	$5.25 +1.7%	$5.42	$0.70 ▼ $17.46	$99.81M	1.17	6.44 million shs	174,950 shs
LRMR Larimar Therapeutics	$4.11 +3.3%	$3.60	$2.71 ▼ $6.42	$413.45M	0.81	1.65 million shs	1.68 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	+4.40%	+3.61%	-4.23%	-11.32%	-8.79%
EPRX Eupraxia Pharmaceuticals	+1.72%	+5.51%	-2.69%	-10.45%	+22.74%
ETHZ Flag Ship Acquisition	0.00%	-9.95%	-14.29%	-6.01%	+515,999,900.00%
LRMR Larimar Therapeutics	+4.19%	+3.92%	+22.09%	-0.75%	+15.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$0.93 -2.8%	$0.97	$0.84 ▼ $2.38	$429.45M	0.81	2.19 million shs	2.08 million shs
EPRX Eupraxia Pharmaceuticals	$6.52 +0.2%	$6.44	$5.04 ▼ $9.32	$423.27M	1.08	360,517 shs	258,770 shs
ETHZ Flag Ship Acquisition	$5.25 +1.7%	$5.42	$0.70 ▼ $17.46	$99.81M	1.17	6.44 million shs	174,950 shs
LRMR Larimar Therapeutics	$4.11 +3.3%	$3.60	$2.71 ▼ $6.42	$413.45M	0.81	1.65 million shs	1.68 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	+4.40%	+3.61%	-4.23%	-11.32%	-8.79%
EPRX Eupraxia Pharmaceuticals	+1.72%	+5.51%	-2.69%	-10.45%	+22.74%
ETHZ Flag Ship Acquisition	0.00%	-9.95%	-14.29%	-6.01%	+515,999,900.00%
LRMR Larimar Therapeutics	+4.19%	+3.92%	+22.09%	-0.75%	+15.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGC Canopy Growth	2.17	Hold	N/A	N/A
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	176.07% Upside
ETHZ Flag Ship Acquisition	1.00	Sell	N/A	N/A
LRMR Larimar Therapeutics	3.09	Buy	$12.71	209.35% Upside

Current Analyst Ratings Breakdown

Latest ETHZ, CGC, LRMR, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	EPRX Eupraxia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/14/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/2/2026	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/30/2026	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00
6/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/25/2026	EPRX Eupraxia Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
6/15/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGC Canopy Growth	$251.01M	1.66	N/A	N/A	$1.13 per share	0.82
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
ETHZ Flag Ship Acquisition	$4.11M	24.28	N/A	N/A	$29.12 per share	0.18
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGC Canopy Growth	-$190.29M	-$0.59	N/A	N/A	N/A	-75.27%	-26.95%	-17.20%	8/7/2026 (Confirmed)
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.05	N/A	N/A	N/A	N/A	-87.56%	-51.20%	8/11/2026 (Estimated)
ETHZ Flag Ship Acquisition	-$6.17M	-$159.65	N/A	N/A	N/A	N/A	-185.71%	-83.12%	N/A
LRMR Larimar Therapeutics	-$165.67M	-$2.06	N/A	N/A	N/A	N/A	-134.14%	-96.00%	8/13/2026 (Estimated)

Latest ETHZ, CGC, LRMR, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.39	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	N/A	N/A	N/A	N/A	N/A
8/7/2026	Q1 2027	CGC Canopy Growth	-$0.04	N/A	N/A	N/A	$58.21 million	N/A
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.39	-$0.30	+$0.09	-$0.30	N/A	N/A
6/15/2026	Q4 2026	CGC Canopy Growth	-$0.06	-$0.17	-$0.11	-$0.05	$53.43 million	$51.22 million
5/14/2026	Q1 2026	LRMR Larimar Therapeutics	-$0.53	-$0.31	+$0.22	-$0.31	N/A	N/A
5/12/2026	Q1 2026	EPRX Eupraxia Pharmaceuticals	-$0.22	-$0.23	-$0.01	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETHZ Flag Ship Acquisition	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGC Canopy Growth	0.31	3.34	2.64
EPRX Eupraxia Pharmaceuticals	0.02	19.31	19.31
ETHZ Flag Ship Acquisition	1.11	10.07	10.07
LRMR Larimar Therapeutics	N/A	4.29	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGC Canopy Growth	3.33%
EPRX Eupraxia Pharmaceuticals	N/A
ETHZ Flag Ship Acquisition	4.07%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
CGC Canopy Growth	0.16%
EPRX Eupraxia Pharmaceuticals	N/A
ETHZ Flag Ship Acquisition	15.10%
LRMR Larimar Therapeutics	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGC Canopy Growth	1,128	448.42 million	447.70 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	65.02 million	N/A	N/A
ETHZ Flag Ship Acquisition	7	19.01 million	16.14 million	N/A
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable

ETHZ, CGC, LRMR, and EPRX Headlines

Recent News About These Companies

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

August 4 at 7:00 AM | globenewswire.com

SummitTX Capital L.P. Invests $1.71 Million in Larimar Therapeutics, Inc. $LRMR

July 30, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 23, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 16, 2026 | prnewswire.com

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

July 16, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 14, 2026 | globenewswire.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Recommendation of "Buy" by Brokerages

July 12, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 9, 2026 | prnewswire.com

Larimar Therapeutics (NASDAQ:LRMR) Director Buys 50,000 Shares

July 9, 2026 | insidertrades.com

AIGH Capital Management LLC Boosts Stake in Larimar Therapeutics, Inc. $LRMR

July 9, 2026 | marketbeat.com

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

July 8, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 7, 2026 | globenewswire.com

Here’s What Citi Thinks About Larimar Therapeutics (LRMR)

July 3, 2026 | finance.yahoo.com

LRMR shares hold steady as Wall Street optimism offsets drug safety concerns

July 2, 2026 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 1, 2026 | prnewswire.com

Larimar's rare disease push just hit a key inflection point — what investors need to know

June 29, 2026 | msn.com

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

June 29, 2026 | finance.yahoo.com

Larimar Therapeutics shares drop following clinical update and regulatory filing (LRMR)

June 29, 2026 | msn.com

Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript

June 29, 2026 | seekingalpha.com

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia

June 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETHZ, CGC, LRMR, and EPRX Company Descriptions

Canopy Growth NASDAQ:CGC

$0.93 -0.03 (-2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$0.93 +0.00 (+0.18%)

As of 07:57 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$6.52 +0.01 (+0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$6.73 +0.21 (+3.21%)

As of 07:58 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Flag Ship Acquisition NASDAQ:ETHZ

$5.25 +0.09 (+1.74%)

As of 08/3/2026

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Larimar Therapeutics NASDAQ:LRMR

$4.11 +0.13 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$4.05 -0.06 (-1.53%)

As of 07:56 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ETHZ, CGC, LRMR, and EPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ETHZ, CGC, LRMR, and EPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ETHZ, CGC, LRMR, and EPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETHZ, CGC, LRMR, and EPRX Company Descriptions

Canopy Growth NASDAQ:CGC

Eupraxia Pharmaceuticals NASDAQ:EPRX

Flag Ship Acquisition NASDAQ:ETHZ

Larimar Therapeutics NASDAQ:LRMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ETHZ, CGC, LRMR, and EPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ETHZ, CGC, LRMR, and EPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ETHZ, CGC, LRMR, and EPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETHZ, CGC, LRMR, and EPRX Company Descriptions

Canopy Growth NASDAQ:CGC

Eupraxia Pharmaceuticals NASDAQ:EPRX

Flag Ship Acquisition NASDAQ:ETHZ

Larimar Therapeutics NASDAQ:LRMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools